Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 138 articles: HTML format Text format

Single Articles

August 2018
1. GAUDET MM, Deubler EL, Kelly RS, Diver WR, et al
   Blood Levels of Cadmium and Lead in Relation to Breast Cancer Risk in Three Prospective Cohorts.
   Int J Cancer. 2018 Aug 17. doi: 10.1002/ijc.31805.
   PubMed     Text format     Abstract available
   
   
   
2. PEDERSEN MH, Hood BL, Ehmsen S, Beck HC, et al
   CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
   Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31798.
   PubMed     Text format     Abstract available
   
   
   
3. CORTESI L, Canossi B, Battista R, Pecchi A, et al
   Breast ultrasonography in the screening protocol for women at hereditary- familial risk of breast cancer: Has the time come to rethink the role of BU according to different risk categories?
   Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31794.
   PubMed     Text format     Abstract available
   
   
   
4. LEE WH, Chen LC, Lee CJ, Huang CC, et al
   DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.
   Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31788.
   PubMed     Text format     Abstract available
   
   
   
5. REUSTLE A, Fisel P, Renner O, Buttner F, et al
   Characterization of the Breast Cancer Resistance Protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
   Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31741.
   PubMed     Text format     Abstract available
   
   
   
6. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
   Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
   Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
   PubMed     Text format     Abstract available
   
   
   July 2018
7. BASU P, Selmouni F, Belakhel L, Sauvaget C, et al
   Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance.
   Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31749.
   PubMed     Text format     Abstract available
   
   
   
8. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
   Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
   Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
   PubMed     Text format    
   
   
   
9. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
   Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
   Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
   PubMed     Text format     Abstract available
   
   
   
10. MCCORMACK V, Febvey-Combes O, Ginsburg O, Dos-Santos-Silva I, et al
    Breast cancer in women living with HIV: A first global estimate.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31722.
    PubMed     Text format     Abstract available
    
    
    
11. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed     Text format    
    
    
    
12. LAN B, Ma F, Chen S, Wang W, et al
    Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31639.
    PubMed     Text format     Abstract available
    
    
    
13. SALEM Y, Yacov N, Propheta-Meiran O, Breitbart E, et al
    Newly Characterized Motile Sperm Domain-Containing Protein 2 Promotes Human Breast Cancer Metastasis.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31665.
    PubMed     Text format     Abstract available
    
    
    
14. FARVID MS, Chen WY, Rosner BA, Tamimi RM, et al
    Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31653.
    PubMed     Text format     Abstract available
    
    
    
15. PARK YH, Lee KH, Sohn JH, Lee KS, et al
    A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31651.
    PubMed     Text format     Abstract available
    
    
    
16. VANGANGELT KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, et al
    The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31658.
    PubMed     Text format     Abstract available
    
    
    
17. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Text format     Abstract available
    
    
    
18. KISO M, Tanaka S, Saji S, Toi M, et al
    Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31645.
    PubMed     Text format     Abstract available
    
    
    June 2018
19. LIPTON A, Leitzel K, Ali SM, Polimera HV, et al
    High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts.
    Int J Cancer. 2018 Jun 20. doi: 10.1002/ijc.31627.
    PubMed     Text format     Abstract available
    
    
    May 2018
20. VON NEUBECK B, Gondi G, Riganti C, Pan C, et al
    An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31607.
    PubMed     Text format     Abstract available
    
    
    
21. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    PubMed     Text format     Abstract available
    
    
    
22. LI J, Jing R, Wei H, Wang M, et al
    Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
    Int J Cancer. 2018 May 12. doi: 10.1002/ijc.31601.
    PubMed     Text format     Abstract available
    
    
    
23. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    PubMed     Text format     Abstract available
    
    
    
24. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Text format     Abstract available
    
    
    
25. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Text format     Abstract available
    
    
    
26. FAN C, Zhang J, Ouyang T, Li J, et al
    RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Int J Cancer. 2018 May 4. doi: 10.1002/ijc.31579.
    PubMed     Text format     Abstract available
    
    
    April 2018
27. BAGLIA ML, Cook LS, Tang MT, Wiggins C, et al
    Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer.
    Int J Cancer. 2018 Apr 30. doi: 10.1002/ijc.31575.
    PubMed     Text format     Abstract available
    
    
    
28. CAIRAT M, Fournier A, Murphy N, Biessy C, et al
    Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31570.
    PubMed     Text format     Abstract available
    
    
    
29. LI J, Wang W, Xia P, Wan L, et al
    Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in breast cancer patients.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31573.
    PubMed     Text format     Abstract available
    
    
    
30. AL-AWADHI A, Murray JL, Ibrahim NK
    Developing Anti-HER2 Vaccines: Breast Cancer Experience.
    Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31551.
    PubMed     Text format     Abstract available
    
    
    
31. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
    A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
    PubMed     Text format     Abstract available
    
    
    
32. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
    Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
    PubMed     Text format     Abstract available
    
    
    
33. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
    Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
    PubMed     Text format     Abstract available
    
    
    
34. CAO C, Wu H, Vasilatos SN, Chandran U, et al
    HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419.
    PubMed     Text format     Abstract available
    
    
    
35. NJOR SH, Paci E, Rebolj M
    As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31420.
    PubMed     Text format     Abstract available
    
    
    March 2018
36. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
    Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
    PubMed     Text format     Abstract available
    
    
    
37. YUE W, Wang J, Atkins KA, Bottalico L, et al
    Effect of a tissue selective estrogen complex (TSEC) on breast cancer: Role of unique properties of conjugated equine estrogen.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31401.
    PubMed     Text format     Abstract available
    
    
    
38. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
    Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
    PubMed     Text format     Abstract available
    
    
    
39. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Text format     Abstract available
    
    
    
40. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Text format     Abstract available
    
    
    
41. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Text format     Abstract available
    
    
    
42. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
    Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
    PubMed     Text format     Abstract available
    
    
    February 2018
43. GATHIRUA-MWANGI WG, Song Y, Monahan P, Champion VL, et al
    Associations of Metabolic syndrome and C-reactive protein with Mortality from total cancer, obesity-linked cancers and Breast Cancer among Women in NHANES III.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31344.
    PubMed     Text format     Abstract available
    
    
    
44. LAN B, Ma F, Zhai X, Li Q, et al
    The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Int J Cancer. 2018 Feb 3. doi: 10.1002/ijc.31291.
    PubMed     Text format     Abstract available
    
    
    January 2018
45. RIAHI A, Radmanesh H, Schurmann P, Bogdanova N, et al
    Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31273.
    PubMed     Text format     Abstract available
    
    
    
46. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
    Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
    PubMed     Text format     Abstract available
    
    
    
47. TERVASMAKI A, Mantere T, Hartikainen JM, Kauppila S, et al
    Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31259.
    PubMed     Text format     Abstract available
    
    
    
48. JOHN EM, Hines LM, Phipps AI, Koo J, et al
    Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2018 Jan 13. doi: 10.1002/ijc.31258.
    PubMed     Text format     Abstract available
    
    
    
49. MURTO MO, Artama M, Pukkala E, Visvanathan K, et al
    Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study.
    Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31250.
    PubMed     Text format     Abstract available
    
    
    
50. GE W, Clendenen TV, Afanasyeva Y, Koenig KL, et al
    Circulating Anti-Mullerian Hormone and Breast Cancer Risk: A Study in Ten Prospective Cohorts.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31249.
    PubMed     Text format     Abstract available
    
    
    
51. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available
    
    
    December 2017
52. ANDERSON C, Engel SM, Anders CK, Nichols HB, et al
    Live birth outcomes after adolescent and young adult breast cancer.
    Int J Cancer. 2017 Dec 21. doi: 10.1002/ijc.31227.
    PubMed     Text format     Abstract available
    
    
    
53. CHEN J, Yao Q, Huang M, Wang B, et al
    A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients with Breast Cancer (CBCRT01).
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31217.
    PubMed     Text format     Abstract available
    
    
    
54. XIE X, Tan W, Chen B, Huang X, et al
    Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31208.
    PubMed     Text format     Abstract available
    
    
    
55. MA L, Fu Q, Xu B, Zhou H, et al
    Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31207.
    PubMed     Text format     Abstract available
    
    
    
56. DALLASPEZIA S, Cantamessa S, Benedetti F
    Light Therapy and Mood in Breast Cancer.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31188.
    PubMed     Text format    
    
    
    
57. MCKENZIE F, Zietsman A, Galukande M, Anele A, et al
    Drivers of advanced stage at breast cancer diagnosis in the multi-country African Breast Cancer - Disparities in Outcomes (ABC-DO) study.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31187.
    PubMed     Text format     Abstract available
    
    
    November 2017
58. LEE KR, Hwang IC, Do Han K, Jung J, et al
    Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
    Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
    PubMed     Text format     Abstract available
    
    
    
59. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
    Life course evolution of body size and breast cancer survival in the E3N cohort.
    Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
    PubMed     Text format     Abstract available
    
    
    
60. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Text format     Abstract available
    
    
    
61. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    PubMed     Text format     Abstract available
    
    
    
62. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    PubMed     Text format     Abstract available
    
    
    
63. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available
    
    
    October 2017
64. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
    Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
    Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
    PubMed     Text format     Abstract available
    
    
    
65. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
    Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
    Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
    PubMed     Text format     Abstract available
    
    
    
66. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
    Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
    PubMed     Text format     Abstract available
    
    
    
67. YU J, Wang X, Lu Q, Wang J, et al
    Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
    PubMed     Text format     Abstract available
    
    
    
68. SUROWY H, Varga D, Burwinkel B, Marme F, et al
    A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
    PubMed     Text format     Abstract available
    
    
    
69. ZHAO B, Zhao H
    Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
    PubMed     Text format     Abstract available
    
    
    
70. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
    ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
    Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
    PubMed     Text format     Abstract available
    
    
    
71. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    PubMed     Text format     Abstract available
    
    
    September 2017
72. THAPA B, Bahadur Kc R, Uludag H
    Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
    PubMed     Text format     Abstract available
    
    
    
73. GUO S, Jing Y, Burcus NI, Lassiter BP, et al
    Nano-Pulse Stimulation Induces Potent Immune Responses, Eradicating Local Breast Cancer while Reducing Distant Metastases.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31071.
    PubMed     Text format     Abstract available
    
    
    
74. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
    Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
    PubMed     Text format     Abstract available
    
    
    
75. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
    Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
    PubMed     Text format     Abstract available
    
    
    
76. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Text format     Abstract available
    
    
    
77. DE GOOIJER MC, Zhang P, Weijer R, Buil LCM, et al
    The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31052.
    PubMed     Text format     Abstract available
    
    
    
78. WANG S, Huo D, Kupfer S, Alleyne D, et al
    Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
    Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
    PubMed     Text format     Abstract available
    
    
    
79. LAGENDIJK M, van Maaren MC, Saadatmand S, Strobbe LJ, et al
    Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.
    Int J Cancer. 2017 Sep 7. doi: 10.1002/ijc.31034.
    PubMed     Text format     Abstract available
    
    
    August 2017
80. BERTRAND KA, Gerlovin H, Bethea TN, Palmer JR, et al
    Pubertal growth and adult height in relation to breast cancer risk in African American women.
    Int J Cancer. 2017 Aug 28. doi: 10.1002/ijc.31019.
    PubMed     Text format     Abstract available
    
    
    
81. WU AH, Vigen C, Butler LM, Tseng CC, et al
    Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans.
    Int J Cancer. 2017 Aug 26. doi: 10.1002/ijc.31018.
    PubMed     Text format     Abstract available
    
    
    
82. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
    Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
    Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
    PubMed     Text format     Abstract available
    
    
    
83. ZHENG G, Yu H, Hemminki A, Forsti A, et al
    Familial associations of female breast cancer with other cancers.
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30927.
    PubMed     Text format     Abstract available
    
    
    
84. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Text format     Abstract available
    
    
    
85. WHITE AJ, Weinberg CR, Park YM, D'Aloisio AA, et al
    Sleep characteristics, light at night and breast cancer risk in a prospective cohort.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30920.
    PubMed     Text format     Abstract available
    
    
    July 2017
86. NILENDU P, Kumar A, Kumar A, Pal JK, et al
    Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30898.
    PubMed     Text format     Abstract available
    
    
    
87. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ, et al
    Reply to Letter to Editor: 'Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.'
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30873.
    PubMed     Text format    
    
    
    
88. SANDSVEDEN M, Manjer J
    Selenium and breast cancer risk: A prospective nested case-control study on serum selenium levels, smoking habits and overweight.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30875.
    PubMed     Text format     Abstract available
    
    
    
89. AUTIER P, Boniol M
    Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30874.
    PubMed     Text format    
    
    
    
90. SCHIROSI L, De Summa S, Tommasi S, Paradiso A, et al
    VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30868.
    PubMed     Text format     Abstract available
    
    
    
91. BARRDAHL M, Rudolph A, Hopper JL, Southey MC, et al
    Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30859.
    PubMed     Text format     Abstract available
    
    
    June 2017
92. FELLER A, Schmidlin K, Bordoni A, Bouchardy C, et al
    Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: A Swiss population-based study.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30856.
    PubMed     Text format     Abstract available
    
    
    
93. ALMOZYAN S, Colak D, Mansour F, Alaiya A, et al
    PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Int J Cancer. 2017 Jun 14. doi: 10.1002/ijc.30834.
    PubMed     Text format     Abstract available
    
    
    May 2017
94. KNIGHT JA, Fan J, Malone KE, John EM, et al
    Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE Study.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30791.
    PubMed     Text format     Abstract available
    
    
    
95. VAN DEN ENDE C, Oordt-Speets AM, Vroling H, van Agt HME, et al
    Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30794.
    PubMed     Text format     Abstract available
    
    
    
96. LOLAS HAMAMEH S, Renbaum P, Kamal L, Dweik D, et al
    Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30771.
    PubMed     Text format     Abstract available
    
    
    
97. BEAU AB, Lynge E, Njor SH, Vejborg I, et al
    Benefit-to-harm ratio of the Danish breast cancer screening programme.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30758.
    PubMed     Text format     Abstract available
    
    
    April 2017
98. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, et al
    The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30754.
    PubMed     Text format     Abstract available
    
    
    
99. NARKHEDE AA, Shevde LA, Rao SS
    Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30748.
    PubMed     Text format     Abstract available
    
    
    March 2017
100. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
     Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
     Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
     PubMed     Text format     Abstract available
     
     
     
101. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
     Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
     Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
     PubMed     Text format     Abstract available
     
     
     
102. PARK YM, White AJ, Nichols HB, O'Brien KM, et al
     The association between metabolic health, obesity phenotype and the risk of breast cancer.
     Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30684.
     PubMed     Text format     Abstract available
     
     
     
103. GADEYNE S, Menvielle G, Kulhanova I, Bopp M, et al
     The turn of the gradient? Educational differences in breast cancer mortality in 18 European populations during the 2000s.
     Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30685.
     PubMed     Text format     Abstract available
     
     
     
104. WANG J, Shidfar A, Ivancic D, Ranjan M, et al
     Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
     Int J Cancer. 2017 Mar 6. doi: 10.1002/ijc.30680.
     PubMed     Text format     Abstract available
     
     
     
105. VAN DEN BRANDT PA, Schulpen M
     Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis.
     Int J Cancer. 2017 Mar 5. doi: 10.1002/ijc.30654.
     PubMed     Text format     Abstract available
     
     
     February 2017
106. STROTBEK M, Schmid S, Sanchez-Gonzalez I, Boerries M, et al
     miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.
     Int J Cancer. 2017 Feb 22. doi: 10.1002/ijc.30661.
     PubMed     Text format     Abstract available
     
     
     
107. LIN X, Chen W, Wei F, Zhou BP, et al
     POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.
     Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30658.
     PubMed     Text format     Abstract available
     
     
     January 2017
108. ROSNER B, Eliassen AH, Toriola AT, Chen WY, et al
     Weight and weight changes in early adulthood and later breast cancer risk.
     Int J Cancer. 2017 Jan 30. doi: 10.1002/ijc.30627.
     PubMed     Text format     Abstract available
     
     
     
109. HALPERN N, Sonnenblick A, Uziely B, Divinsky L, et al
     Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
     Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30616.
     PubMed     Text format     Abstract available
     
     
     December 2016
110. BENNETT L, Quinn J, McCall P, Mallon EA, et al
     High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
     Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30578.
     PubMed     Text format     Abstract available
     
     
     
111. XU W, Jia G, Cai N, Huang S, et al
     A 16 Yin Yang Gene Expression Ratio Signature for ER+/Node- Breast Cancer.
     Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30556.
     PubMed     Text format     Abstract available
     
     
     
112. CHEN S, Wang RX, Liu Y, Yang WT, et al
     PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
     Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30552.
     PubMed     Text format     Abstract available
     
     
     
113. MATEJCIC M, de Batlle J, Ricci C, Biessy C, et al
     Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort.
     Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30536.
     PubMed     Text format     Abstract available
     
     
     November 2016
114. KARASNEH RA, Murray LJ, Cardwell CR
     Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.
     Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30520.
     PubMed     Text format     Abstract available
     
     
     
115. VAN LUIJT PA, Heijnsdijk EA, de Koning HJ
     Cost-effectiveness of the Norwegian breast cancer screening program.
     Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30513.
     PubMed     Text format     Abstract available
     
     
     
116. YANG H, Brand JS, Fang F, Chiesa F, et al
     Time-dependent risk of depression, anxiety and stress-related disorders in patients with invasive and in-situ breast cancer.
     Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30514.
     PubMed     Text format     Abstract available
     
     
     
117. BODELON C, Oh H, Chatterjee N, Garcia-Closas M, et al
     Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.
     Int J Cancer. 2016 Nov 9. doi: 10.1002/ijc.30512.
     PubMed     Text format     Abstract available
     
     
     
118. BHUSARI P, Vatsa R, Singh G, Parmar M, et al
     Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
     Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500.
     PubMed     Text format     Abstract available
     
     
     October 2016
119. FERRONI P, Santilli F, Cavaliere F, Simeone P, et al
     Oxidant stress as a major determinant of platelet activation in invasive breast cancer.
     Int J Cancer. 2016 Oct 26. doi: 10.1002/ijc.30488.
     PubMed     Text format     Abstract available
     
     
     September 2016
120. SIMONSSON M, Bjorner S, Markkula A, Nodin B, et al
     The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
     Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30432.
     PubMed     Text format     Abstract available
     
     
     
121. VAN DER WAAL D, Ripping TM, Verbeek AL, Broeders MJ, et al
     Breast cancer screening effect across breast density strata: A case-control study.
     Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30430.
     PubMed     Text format     Abstract available
     
     
     
122. STRAND F, Humphreys K, Eriksson M, Li J, et al
     Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer.
     Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30427.
     PubMed     Text format     Abstract available
     
     
     
123. SYNNOTT NC, Murray A, McGowan PM, Kiely M, et al
     Mutant p53: A Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer?
     Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30425.
     PubMed     Text format     Abstract available
     
     
     
124. ROMIEU I, Ferrari P, Chajes V, de Batlle J, et al
     Fiber intake modulates the association of alcohol intake with breast cancer.
     Int J Cancer. 2016 Sep 6. doi: 10.1002/ijc.30415.
     PubMed     Text format     Abstract available
     
     
     
125. HE W, Lindstrom LS, Hall P, Czene K, et al
     Cause-specific mortality in women with breast cancer in situ.
     Int J Cancer. 2016 Sep 4. doi: 10.1002/ijc.30413.
     PubMed     Text format     Abstract available
     
     
     August 2016
126. NOMURA SJ, Dash C, Rosenberg L, Yu J, et al
     Adherence to diet, physical activity and body weight recommendations and breast cancer incidence in the Black Women's Health Study.
     Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30410.
     PubMed     Text format     Abstract available
     
     
     
127. FRY EA, Taneja P, Inoue K
     Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
     Int J Cancer. 2016 Aug 23. doi: 10.1002/ijc.30399.
     PubMed     Text format     Abstract available
     
     
     
128. KIISKI JI, Fagerholm R, Tervasmaki A, Pelttari LM, et al
     FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
     Int J Cancer. 2016 Aug 20. doi: 10.1002/ijc.30394.
     PubMed     Text format     Abstract available
     
     
     
129. KIM HJ, Min A, Im SA, Jang H, et al
     Anti-tumor Activity of the ATR Inhibitor AZD6738 in HER2 positive Breast Cancer Cells.
     Int J Cancer. 2016 Aug 8. doi: 10.1002/ijc.30373.
     PubMed     Text format     Abstract available
     
     
     
130. LI J, Humphreys K, Eriksson M, Dar H, et al
     Worse quality of life in young and recently-diagnosed breast cancer survivors compared to female survivors of other cancers: A cross-sectional study.
     Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30370.
     PubMed     Text format     Abstract available
     
     
     July 2016
131. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
     Serum NSE, MMP-9 and HER2 extra-cellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases?
     Int J Cancer. 2016 Jul 27. doi: 10.1002/ijc.30290.
     PubMed     Text format     Abstract available
     
     
     
132. CADEAU C, Fournier A, Mesrine S, Clavel-Chapelon F, et al
     Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
     Int J Cancer. 2016 Jul 23. doi: 10.1002/ijc.30282.
     PubMed     Text format     Abstract available
     
     
     
133. KIM SB, Wildiers H, Krop IE, Smitt M, et al
     Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
     Int J Cancer. 2016 Jul 18. doi: 10.1002/ijc.30276.
     PubMed     Text format     Abstract available
     
     
     
134. AYRAULT-PIAULT S, Grosclaude P, Daubisse-Marliac L, Pascal J, et al
     Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France).
     Int J Cancer. 2016 Jul 12. doi: 10.1002/ijc.30266.
     PubMed     Text format     Abstract available
     
     
     
135. INOUE K, Fry EA
     Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
     Int J Cancer. 2016;139:33-41.
     PubMed     Text format     Abstract available
     
     
     June 2016
136. ABREU MH, Abreu PH, Afonso N, Pereira D, et al
     Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?
     Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30225.
     PubMed     Text format     Abstract available
     
     
     May 2016
137. MANTHRAVADI S, Shrestha A, Madhusudhana S
     Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.
     Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30185.
     PubMed     Text format     Abstract available
     
     
     
138. JOYCE DP, Kerin MJ, Dwyer RM
     Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.
     Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30179.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: